Mark J. Ratain to Dipeptides
This is a "connection" page, showing publications Mark J. Ratain has written about Dipeptides.
Connection Strength
0.242
-
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
Score: 0.242